ArticleBMJ open gastroenterology2023

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13).

Isabel Carbery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.